Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
46.7M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
25.3M
-
Shares change
-
+1.37M
-
Total reported value, excl. options
-
$382M
-
Value change
-
+$19.4M
-
Put/Call ratio
-
0
-
Number of buys
-
37
-
Number of sells
-
-29
-
Price
-
$15.12
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q1 2022
81 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.3M shares
of 46.7M outstanding shares and own 54.13% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (3.94M shares), BVF INC/IL (2.66M shares), Deep Track Capital, LP (2.45M shares), BlackRock Inc. (2.13M shares), Aquilo Capital Management, LLC (1.76M shares), JANUS HENDERSON GROUP PLC (1.67M shares), Octagon Capital Advisors LP (1.57M shares), STATE STREET CORP (1.49M shares), VANGUARD GROUP INC (1.29M shares), and ArrowMark Colorado Holdings LLC (1.15M shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.